2 May 2022 - Gilead Science Korea said its hepatitis B treatment Vemlidy (tenofovir alafenamide) started receiving expanded health insurance coverage for treating patients with decompensated cirrhosis and hepatitis B with hepatocellular carcinoma on Sunday.
The government expanded the reimbursement standard following the change in the detailed recognition standards for medical care benefits for oral chronic hepatitis B treatment.